Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Common Equity (2017 - 2024)

Solid Biosciences' Common Equity history spans 8 years, with the latest figure at $167.0 million for Q3 2024.

  • For Q3 2024, Common Equity rose 15.7% year-over-year to $167.0 million; the TTM value through Sep 2024 reached $167.0 million, up 15.7%, while the annual FY2023 figure was $126.5 million, 40.25% down from the prior year.
  • Common Equity for Q3 2024 was $167.0 million at Solid Biosciences, down from $193.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $253.0 million in Q1 2021 and bottomed at $22.2 million in Q3 2020.
  • The 5-year median for Common Equity is $167.0 million (2024), against an average of $161.4 million.
  • The largest annual shift saw Common Equity tumbled 79.52% in 2020 before it surged 904.74% in 2021.
  • A 5-year view of Common Equity shows it stood at $132.1 million in 2020, then surged by 57.63% to $208.2 million in 2021, then grew by 1.66% to $211.7 million in 2022, then tumbled by 40.25% to $126.5 million in 2023, then soared by 32.05% to $167.0 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Common Equity are $167.0 million (Q3 2024), $193.2 million (Q2 2024), and $210.7 million (Q1 2024).